Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
CA.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BM.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.46NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CU.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CA.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.83NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.40NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.160.27NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-1668.53US
AY.4.2.4 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.161NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.58NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.75NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.411NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.217NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.35NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.17 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.41NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.527NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.18NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.500NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-19690.7US
B.1.1.147NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.487NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.68NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-1668.53US
B.1.1.121NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AA.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AS.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.115NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.127.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.88NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.338NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BG.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.20.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XVNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.38.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4.1.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.80NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.134NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-1668.53US
CZ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BY.1.2.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BM.1.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BM.2.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CW.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.42NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XAY.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CH.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.46NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBC.1.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.258.14NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.17.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used